Prueksaritanont, Thomayant

Glucuronidation of Statins in Animals and Humans: A Novel Mechanism of Statin Lactonization

Prueksaritanont, T., Subramanian, R., Fang, X., Ma, B., Qiu, Y., Lin, J. H., Pearson, P. G., & Baillie, T. A. (2002) · Drug Metabolism and Disposition

Pharmacogenetics and Drug MetabolismDrug Transport and Resistance Mechanisms

Cited by 344

The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, and not CYP2D6

Prueksaritanont, T., Ma, B., & Yu, N. (2003) · British Journal of Clinical Pharmacology

Pharmacogenetics and Drug MetabolismDrug-Induced Hepatotoxicity and Protection

Cited by 180

Simvastatin Does Not Have a Clinically Significant Pharmacokinetic Interaction With Fenofibrate in Humans

Bergman, A. J., Murphy, G., Burke, J., Zhao, J. J., Valesky, R., Liu, L., Lasseter, K. C., He, W., Prueksaritanont, T., Qiu, Y., et al. (2004) · The Journal of Clinical Pharmacology

Lipoproteins and Cardiovascular HealthPharmacogenetics and Drug Metabolism

Cited by 97

Pharmacokinetic de-risking tools for selection of monoclonal antibody lead candidates

Dostalek, M., Prueksaritanont, T., & Kelley, R. F. (2017) · mAbs

Monoclonal and Polyclonal Antibodies ResearchBiosimilars and Bioanalytical Methods

Cited by 45

Interconversion Pharmacokinetics of Simvastatin and its Hydroxy Acid in Dogs: Effects of Gemfibrozil

Prueksaritanont, T., Qiu, Y., Mu, L., Michel, K., Brunner, J., Richards, K. M., & Lin, J. H. (2005) · Pharmaceutical Research

Pharmacogenetics and Drug MetabolismLipoproteins and Cardiovascular Health

Cited by 35